
At Aditum Bio, our mission is to rapidly translate scientific discoveries into new medicines. Co-founded by industry veterans Joe Jimenez, former CEO of Novartis and Mark Fishman, former President of the Novartis Institutes for Biomedical Research, the firm in-licenses promising therapies that for some reason are not advancing toward the clinic. The firm focuses on the translational phase of medicine to generate data that can support full clinical development, and eventual market launch, to reach patients in need.
The Senior Manager, Clinical Operations will play a key role in the planning, execution, and oversight of early-stage clinical trials across assigned Aditum Bio portfolio companies. Reporting to the Senior Director, Clinical Operations, this individual will serve as an operational lead for one or more Phase I and Phase II studies, partnering closely with internal cross-functional teams and external CROs to ensure studies are conducted efficiently, compliantly, and with a high standard of quality. This is a hands-on role that requires strong operational execution, vendor oversight, and the ability to thrive in a fast-paced, lean biotech incubator environment supporting multiple portfolio companies.
Responsibilities
Study Leadership & Execution
Vendor & Cross-Functional Partnership
Quality, Compliance & Data Oversight
Budget & Process
Qualifications
The range for this full-time position is $185,000 - 195,000, plus a target bonus, equity compensation and benefits including medical, dental, vision, and 401k. Our salary ranges are determined by role, level and location. The range displayed on our postings reflects the minimum and maximum for new hire salaries. Within the range, individual pay is determined by interview performance, job-related skills, experience and relevant education and training. Please note the range reflects base salary and does not include target bonus, equity or benefits.
We provide equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.

Aditum Bio — from the Latin word for “access” — was founded on a simple mission: to give patients access to medicines that may not otherwise be developed.
We are a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum Bio brings together unmatched scientific and domain expertise, combined with operational capabilities that accelerate drug development. Our agile, collaborative model enables rapid company formation, planning, and execution, empowering teams to explore promising science and bring therapies to patients faster.
Guided by our core values — Patient Centric, Collaborative, Curious, and Courageous — we focus on advancing clinic-ready therapies that address significant unmet needs. We are patient centric in our purpose, collaborative in our approach, curious in our pursuit of new science, and courageous in taking on high-impact challenges.
Launched in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, Aditum Bio manages a broad and growing portfolio of clinical-stage companies focused on improving health outcomes across diverse therapeutic areas.
For more information, please visit www.aditumbio.com.